Scancell Holdings Merges With Neuphoria Therapeutics Under $89 Million Financing Plan

Chemomab Therapeutics and Scipher Medicine to Merge to Advance Nebokitug in AI-Powered RA Trial

July 9, 2026

Healthcare Services

Chemomab Therapeutics and Scipher Medicine have announced a definitive merger agreement in a stock transaction. The combined company, expected to operate as Scipher Medicine Corporation and trade on Nasdaq, will initially focus on advancing Chemomab’s nebokitug into a Phase 2 rheumatoid arthritis trial using Scipher’s AI Network Medicine platform and PrismRA test.

GSK to Acquire Nuvalent for $10.6 Billion

June 9, 2026

Pharmaceuticals

GSK announced an agreement to acquire clinical-stage biopharmaceutical company Nuvalent for $10.6 billion to expand its lung cancer oncology portfolio. The deal will include three non-small cell lung cancer (NSCLC) programs, led by zidesamtinib and neladalkib, and is expected to drive revenue growth beginning in 2027.

Neurocrine Biosciences to Acquire Celeno Therapeutics

April 7, 2026

Healthcare Services

Neurocrine Biosciences entered into a definitive all-cash agreement to acquire Celeno Therapeutics for approximately $2.9 billion. The deal is structured as a tender offer and is expected to close within ~90 days, subject to Hart-Scott-Rodino antitrust clearance and a majority of Celeno shares being tendered.

Bruker Corporation to Acquire Neurescence Inc.

November 12, 2022

Healthcare Services

Bruker Corporation has signed a definitive agreement to purchase 100% of the shares of Neurescence Inc., an ultralight fiber-bundle Multiscopes provider for simultaneous multi-region optical functional neuroimaging. The acquisition is expected to create synergies with Bruker’s multiphoton and head-mounted miniscope offerings, expanding its reach in freely behaving animal imaging and photostimulation.

Fulgent Genetics Acquires Fulgent Pharma

November 7, 2022

Biotechnology

Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.

BioNTech Acquires Neon Therapeutics

January 16, 2020

Biotechnology

BioNTech SE will acquire Neon Therapeutics, Inc. in an all-stock transaction valued at approximately $67.0 million. Neon, a Cambridge-based developer of neoantigen-targeted T cell therapies, will become a wholly owned subsidiary of BioNTech to expand BioNTech’s T cell therapy capabilities and U.S. presence.